Latest news
ProMIS schedules 4:30 p.m. webcast for Aug. 13 update - Stock TitanStock Titan · Mon, 03 Aug 2026 20:00:00 GMTPMN310 Shows No ARIA Signals in Early Alzheimer’s Phase 1b Trial - The Clinical Trial VanguardThe Clinical Trial Vanguard · Thu, 30 Jul 2026 06:41:50 GMTProMIS Neurosciences Reports Positive 6-Month Interim Safety and Biomarker Results for PMN310 in Phase 1b Alzheimer’s Trial - Quiver QuantitativeQuiver Quantitative · Tue, 28 Jul 2026 10:13:00 GMTProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial - GlobeNewswireGlobeNewswire · Tue, 28 Jul 2026 10:00:00 GMTPositive Safety and Biomarker Phase 1b Results for PMN310 Mild Cognitive Impairment and Alzheimer Disease - Psychiatric TimesPsychiatric Times · Tue, 28 Jul 2026 07:00:00 GMTProMIS Neurosciences (Nasdaq: PMN) reports positive six-month PMN310 Alzheimer’s trial data - Stock TitanStock Titan · Tue, 28 Jul 2026 07:00:00 GMTSmall-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study - SahmSahm · Tue, 28 Jul 2026 07:00:00 GMT